Several new diverse anticonvulsant agents discovered in a virtual screening campaign aimed at novel antiepileptic drugs to treat refractory epilepsy

Journal of Chemical Information and Modeling

Volumn 52, Issue 12, 2012, Pages 3325-3330

  Di Ianni, Mauricio E ^a   Enrique, Andrea V ^a   Palestro, Pablo H ^a   Gavernet, Luciana ^a   Talevi, Alan ^a   Bruno Blanch, Luis E ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEINS; NEUROLOGY; REFRACTORY MATERIALS;

ANTIEPILEPTIC DRUGS; DISCRIMINANT FUNCTIONS; DOCKING SIMULATIONS; DRUG CANDIDATES; P-GLYCOPROTEIN; SEQUENTIAL FILTERING; VIRTUAL FILTERS; VIRTUAL SCREENING;

DRUG PRODUCTS;

ANTICONVULSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER INTERFACE; DRUG SCREENING; EPILEPSY; HUMAN; METABOLISM; METHODOLOGY; MOUSE; PROTEIN CONFORMATION; TREATMENT FAILURE;

ANIMALS; ANTICONVULSANTS; DRUG EVALUATION, PRECLINICAL; EPILEPSY; HUMANS; MICE; MODELS, MOLECULAR; P-GLYCOPROTEIN; PROTEIN CONFORMATION; TREATMENT FAILURE; USER-COMPUTER INTERFACE;

EID: 84871560537     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci300423q     Document Type: Article

References (41)

1. World Health Organization. Fact sheet 999: Epilepsy. 2009.
2. Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Peruccca, E.; Thomson, T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) Epilepsy Res. 2004, 61, 1-48
3. Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Peruccca, E.; Thomson, T. Progress report on new antiepileptic drugs: a summary of the Eight Eilat Conference (EILAT VIII) Epilepsy Res. 2007, 73, 1-52
4. Löscher, W.; Schmidt, D. Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma Epilepsia 2011, 52, 657-678
5. French, J. A. Refractory Epilepsy: Clinical Overview Epilepsia 2007, 48 (Suppl. 1) 3-7
6. Schmidt, D.; Löscher, W. Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms Epilepsia 2005, 46, 858-877
7. Luna-Tortós, C.; Fedrowitz, M.; Löscher, W. Several major antiepileptic drugs are substrates for human P-glycoprotein Neuropharmacology 2008, 55, 1364-1375
8. Cucullo, L.; Hossain, M.; Rapp, E.; Manders, T.; Janigro, D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs Epilepsia 2007, 48, 505-516
9. Baltes, S.; Fedrowitz, M.; Luna-Tortós, C.; Potschka, H.; Löscher, W. J. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays Pharmcol. Exp. Ther. 2007, 320, 331-343
10. Baltes, S.; Gastens, A. M.; Fedrowitz, M.; Potschka, H.; Kaever, V.; Löscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein Neuropharmacology 2007, 52, 333-346
11. Crowe, A.; Teoh, Y. K. Limited P-glycoprotein mediated efflux for anti-epileptic drugs J. Drug Targeting. 2006, 14, 291-300
12. Cerveny, L.; Pavek, P.; Malakova, J.; Staud, F.; Fendrich, Z. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents Epilepsia 2006, 47, 461-468
13. Löscher, W.; Delanty, N. MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion Pharmacogenomics 2009, 10, 711-713
14. Anderson, G. D.; Shen, D. D. Where is the evidence that p-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy? Epilepsia 2007, 48, 2372-2374
15. Schmidt, D.; Löscher, W. New Developments in Antiepileptic Drug Resistance: An Integrative View Epilepsy Curr. 2009, 9, 47-52
16. Marson, A. G. When to start antiepileptic drug treatment and with what evidence? Epilepsia 2008, 49 (Suppl. 9) 3-6
17. Arts, W. F.; Geerts, A. T.; Arts, W. F.; Geerts, A. T. Eur. J. Paediatr. Neurol. 2009, 13, 93-101
18. Tishler, D. M.; Weinkberg, K. I.; Hinton, D. R.; Barbaro, N.; Annett, G. M.; Raffel, C. MDR1 gene expression in brain of patients with medically intractable epilepsy Epilepsia 1995, 36, 1-6
19. Lasarowski, A.; Massaro, M.; Schteinschnaider, A.; Intruvini, S.; Sevlever, G.; Rabinowixz, A. Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy Ther. Drug. Monit. 2004, 26, 44-46
20. Aronica, E.; Gorter, J. A.; Jansen, G. H.; van Veelen, C. W.; van Rijen, P. C.; Leenstra, S.; Ramkena, M.; Scheffer, G. L.; Scheper, R. J.; Troost, D. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors Neuroscience 2003, 118, 417-429
21. Kubota, H.; Ishidara, H.; Langmann, T.; Schmitz, G.; Stieger, B.; Wieser, H. H.; Yonekawa, Y.; Frei, K. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis Epilepsy Res. 2006, 68, 213-228
22. Di Ianni, M. E.; Talevi, A.; Castro, E. A.; Bruno-Blanch, L. E. Development of a highly specific ensemble of topological models for early identification of P-glycoprotein substrates J. Chemometr. 2011, 25, 313-322
23. Talevi, A.; Sella Cravero, M.; Castro, E. A.; Bruno-Blanch, L. E. Discovery of anticonvulsant activity of abietic acid through application of linear discriminant analysis Bioorg. Med. Chem. Lett. 2007, 17, 1684-1690
24. Talevi, A.; Bellera, C. L.; Castro, E. A.; Bruno-Blanch, L. E. A successful virtual screening application: prediction of anticonvulsant activity in MES test of widely used pharmaceutical and food preservatives methylparaben and propylparaben J. Comput.-Aided Mol. Des. 2007, 21, 527-538
25. Gavernet, L.; Talevi, A.; Castro, E. A.; Bruno-Blanch, L. E. A Combined Virtual Screening 2D and 3D QSAR Methodology for the Selection of New Anticonvulsant Candidates from a Natural Product Library QSAR Comb. Sci. 2009, 27, 1120-1129
26. Irwin, J. J.; Shoichet, B. K. ZINC - a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45, 177-182
27. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs Nucleic Acids Res. 2011, 39 (Database issue) D1035-1041
28. Palestro, P.; Gavernet, L.; Estiu, G.; Bruno-Blanch, L. unpublished results.
29. Tropsha, A.; Gramatica, P.; Gombar, V. The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models QSAR Comb. Sci. 2003, 22, 69-77
30. Trott, O.; Olson, A. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading J. Comput. Chem. 2010, 31, 455-461
31. Ambrish, R.; Alper, K.; Yang, Z. I-TASSER: a unified platform for automated protein structure and function prediction Nat. Protoc. 2010, 5, 725-738
32. National Institute of Health, National Institute of NeurologicalDisorders and Stroke. Anticonvulsant Screening Program. http://www.ninds.nih.gov/ research/asp/addadd-review.pdf (accessed April 11, 2012).
33. Isoherranen, N.; Levy, R. H.; Yagen, B.; Woodhead, J. H.; White, H. S.; Bialer, M. Metabolism of a new antiepileptic drug, N-methyl- tetramethylcyclopopanecarboxamide, and anticonvulsant activity of its metabolites Epilepsy Res. 2004, 58, 1-12
34. Talevi, A.; Enrique, A. V.; Bruno-Blanch, L. E. Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 and brain glutamate receptors Bioorg. Med. Chem. Lett. 2012, 22, 4072-4074
35. Kroger, M.; Meister, K.; Kava, R. Low-calorie sweeteners and other sugar substitutes: a review of the safety issues Compr. Rev. Food. Sci. Food Safe 2006, 5, 35-47
36. Mortensen, A. Sweeteners permitted in the European Union: safety aspects Scand. J. Food. Nutr. 2006, 50, 104-116
37. Larigan, R. S.; Yamank, T. A. Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA Int. J. Toxicol. 2002, 21 (Suppl 2) 95-142
38. Cremer, D. R.; Rabeler, R.; Roberts, A.; Lynch, B. Long-term safety of α-lipoic acid (ALA) consumption: a 2-year study Regul. Toxicol. Pharmacol. 2006, 46, 196-201
39. Deftereos, S. N.; Andronis, C.; Friedla, E. J.; Persidis, A.; Persidis, A. Drug repurposing and adverse event prediction using highthroughput literature analysis Wiley Interdiscip. Rev. Sys. Biol. Med. 2011, 3, 323-334
40. Lussier, Y. A.; Chen, J. L. The emergence of genome-based drug repositioning Sci. Transl. Med. 2011, 3, 96ps35
41. Ekins, S.; Williams, A. J.; Krasowski, M. D.; Freundlich, J. S. In silico repositioning of approved drugs for rare and neglected diseases Drug Discov. Today 2011, 16, 298-310